14 recruiting, 7 active not recruiting, 7 completed, 5 terminated. 15 Phase 1, 14 Phase 2, 10 Phase 3, 3 Not applicable, 1 Phase 4.
Follow Urothelial Carcinoma Bladder: new trials by email Literature Review of Urothelial Carcinoma Bladder trials Research Report on Urothelial Carcinoma Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial Calcium electroporation, Intratumoral calcium injection, Transurethral electroporation - Bladder Tumors, Bladder Tumor | Phase 1 | Recruiting | Juan Luis Vásquez | 20 | 2026-10-12 | 2026-10-27 |
| A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC UGN-501 - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 1 | Recruiting | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | 30 | 2026-09-28 | 2026-10-13 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-06-30 | 2026-03-17 | |
| A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-05-01 | 2026-03-17 | |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
| JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes junctional adhesion molecule3 expression by immunhistochemistry - Urothelial Carcinoma Bladder | Not yet recruiting | Zeinab Yahia Zaki | 40 | 2025-10-01 | 2025-03-30 | |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) - Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 150 | 2025-08-22 | 2026-09-17 |
| A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. Gemcitabine + BCG, BCG (TICE strain) - NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Queen's University | 31 | 2025-08-01 | 2025-07-17 |
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-08-24 |
| Bladder EpiCheck European Haematuria Study Bladder EpiCheck - Hematuria, Cystoscopy | Recruiting | Nucleix Ltd. | 800 | 2025-06-20 | 2026-01-22 | |
| Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases Bladder Cancer, Urothelial Carcinoma Bladder | Active not recruiting | Pangea Laboratory LLC | 80 | 2025-06-03 | 2026-01-06 | |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer Concurrent Immunotherapy and Radiation Therapy - Urothelial Carcinoma Bladder, Bladder Cancer | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 10 | 2025-04-29 | 2026-05-14 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma 9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 60 | 2025-01-17 | 2025-03-21 |
| Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity Physical Activity - Urothelial Carcinoma Bladder | Not applicable | Recruiting | Ludwig-Maximilians - University of Munich | 146 | 2024-11-29 | 2026-04-27 |
| Renal Retention in High Grade Upper Tract Urothelial Cancer Enfortumab vedotin, Pembrolizumab - High Grade Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2024-11-25 | 2026-01-08 |
| A Study of VET3-TGI in Patients With Solid Tumors VET3-TGI, Atezolizumab - Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer | Phase 1 | Recruiting | KaliVir Immunotherapeutics | 60 | 2024-09-16 | 2026-04-07 |
Showing 20 of 45. Sign in to see all of them.
Urinary Bladder Neoplasms (27) · Carcinoma, Transitional Cell (13) · Non-Muscle Invasive Bladder Neoplasms (12) · Neoplasms (9) · Carcinoma, Non-Small-Cell Lung (7) · Squamous Cell Carcinoma of Head and Neck (5) · Melanoma (4) · Urologic Neoplasms (4) · Carcinoma, Renal Cell (3) · Stomach Neoplasms (3) · Endometrial Neoplasms (2) · Head and Neck Neoplasms (2) · Hematuria (2) · Kidney Neoplasms (2) · Mesothelioma (2)
Neoplasms by Site (36) · Urogenital Diseases (35) · Female Urogenital Diseases (34) · Female Urogenital Diseases and Pregnancy Complications (34) · Male Urogenital Diseases (34) · Urogenital Neoplasms (33) · Urologic Diseases (32) · Neoplasms (30) · Urologic Neoplasms (28) · Urinary Bladder Diseases (27) · Carcinoma (26) · Neoplasms by Histologic Type (26) · Neoplasms, Glandular and Epithelial (26) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7)
Gemcitabine (7) · Cisplatin (5) · Mitomycin (5) · pembrolizumab (5) · BCG Vaccine (3) · Cystectomy (3) · atezolizumab (3) · Carboplatin (2) · Nivolumab (2) · enfortumab vedotin (2) · Biomarkers (1) · Biopsy, Large-Core Needle (1) · Docetaxel (1) · Etoposide (1) · Exercise (1)
UroGen Pharma Ltd. (6) · Relmada Therapeutics, Inc. (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · SystImmune Inc. (2) · The Methodist Hospital Research Institute (2) · Abramson Cancer Center at Penn Medicine (1) · Aktis Oncology, Inc. (1) · Assiut University (1) · Aura Biosciences (1) · Brown University (1) · Cairo University (1) · Elephas (1) · Fundacio Puigvert (1) · IO Biotech (1) · Ikena Oncology (1)
United States (26) · Spain (5) · Bulgaria (3) · China (3) · Estonia (3) · Georgia (3) · Latvia (3) · Canada (2) · Israel (2) · Italy (2) · Poland (2) · Serbia (2) · United Kingdom (2) · Australia (1) · Austria (1)
Sebastian Mirkin, MD (3) · Jean Hoffman-Censits, MD (2) · Sandip Prasad, MD (2) · Ahmed M Eltaher, professor (1) · Alexandre R Zlotta, MD, PhD, FRCSC (1) · Elyse Seltzer, MD (1) · Fred Hausheer, MD, FACP (1) · Girish S Kulkarni, MD (1) · Hirak Der-Torossian, MD (1) · Hosny A Behnsawy, associate professor (1) · Jeffrey R. Karnes, M.D. (1) · Jimmy Liu Zhao, MD, PhD (1) · Joao P Zambon, MD (1) · John Christodouleas, MD (1) · Jonathan W Riess, MD, MSc (1)
PMID 1612951, PMID 29188298, PMID 31100252, PMID 34433303, PMID 35618567, PMID 35640276, PMID 35703113, PMID 37468392, PMID 37548555, PMID 38265030, PMID 38849479, PMID 39353477, PMID 39446087, PMID 40048558, PMID 40791544, PMID 41074972, PMID 41484629, PMID 41880645, PMID 42166701